Overview

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Status:
Recruiting

Trial end date:
2029-01-31

Target enrollment:

Participant gender:

Summary

This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.

Phase:

Phase 2

Details

Lead Sponsor:

Technische Universität Dresden

Collaborator:

Roche Pharma AG

Treatments:

Atezolizumab